339 related articles for article (PubMed ID: 34592229)
1. Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer.
Akbarzadeh M; Mihanfar A; Akbarzadeh S; Yousefi B; Majidinia M
Life Sci; 2021 Nov; 285():119984. PubMed ID: 34592229
[TBL] [Abstract][Full Text] [Related]
2. Small molecules with huge impacts: the role of miRNA-regulated PI3K pathway in human malignancies.
Kashani B; Zandi Z; Kaveh V; Pourbagheri-Sigaroodi A; Ghaffari SH; Bashash D
Mol Biol Rep; 2021 Dec; 48(12):8045-8059. PubMed ID: 34689281
[TBL] [Abstract][Full Text] [Related]
3. The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy.
Javadinia SA; Shahidsales S; Fanipakdel A; Mostafapour A; Joudi-Mashhad M; Ferns GA; Avan A
Curr Pharm Des; 2018; 24(39):4646-4651. PubMed ID: 30636576
[TBL] [Abstract][Full Text] [Related]
4. The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
Shorning BY; Dass MS; Smalley MJ; Pearson HB
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630372
[TBL] [Abstract][Full Text] [Related]
5. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-133a alleviates airway remodeling in asthtama through PI3K/AKT/mTOR signaling pathway by targeting IGF1R.
Shao Y; Chong L; Lin P; Li H; Zhu L; Wu Q; Li C
J Cell Physiol; 2019 Apr; 234(4):4068-4080. PubMed ID: 30146725
[TBL] [Abstract][Full Text] [Related]
7. The emerging role of non-coding RNAs in the regulation of PI3K/AKT pathway in the carcinogenesis process.
Ghafouri-Fard S; Abak A; Tondro Anamag F; Shoorei H; Majidpoor J; Taheri M
Biomed Pharmacother; 2021 May; 137():111279. PubMed ID: 33493969
[TBL] [Abstract][Full Text] [Related]
8. The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles.
Sanaei MJ; Baghery Saghchy Khorasani A; Pourbagheri-Sigaroodi A; Shahrokh S; Zali MR; Bashash D
J Cell Physiol; 2022 Mar; 237(3):1720-1752. PubMed ID: 34897682
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
Li YJ; Wang Y; Wang YY
J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
[TBL] [Abstract][Full Text] [Related]
10. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
11. Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway.
He W; Fu Y; Zheng Y; Wang X; Liu B; Zeng J
BMC Cancer; 2021 Feb; 21(1):125. PubMed ID: 33549034
[TBL] [Abstract][Full Text] [Related]
12. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
13. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Ciruelos Gil EM
Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
[TBL] [Abstract][Full Text] [Related]
15. Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.
Raith F; O'Donovan DH; Lemos C; Politz O; Haendler B
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768610
[TBL] [Abstract][Full Text] [Related]
16. Natural products targeting autophagy via the PI3K/Akt/mTOR pathway as anticancer agents.
Sun H; Wang Z; Yakisich JS
Anticancer Agents Med Chem; 2013 Sep; 13(7):1048-56. PubMed ID: 23293890
[TBL] [Abstract][Full Text] [Related]
17. The Role of mTOR Signaling as a Therapeutic Target in Cancer.
Popova NV; Jücker M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572326
[TBL] [Abstract][Full Text] [Related]
18. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
[TBL] [Abstract][Full Text] [Related]
19. Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis.
Ocana A; Vera-Badillo F; Al-Mubarak M; Templeton AJ; Corrales-Sanchez V; Diez-Gonzalez L; Cuenca-Lopez MD; Seruga B; Pandiella A; Amir E
PLoS One; 2014; 9(4):e95219. PubMed ID: 24777052
[TBL] [Abstract][Full Text] [Related]
20. Review: The PI3K-AKT-mTOR signal transduction pathway in canine cancer.
Meuten TK; Dean GA; Thamm DH
Vet Pathol; 2024 May; 61(3):339-356. PubMed ID: 37905509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]